Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Return on Capital Employed data on record, last reported at 0.49% in Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 115.0% year-over-year to 0.49%; the TTM value through Sep 2025 reached 0.49%, up 115.0%, while the annual FY2023 figure was 0.47%, N/A changed from the prior year.
  • Return on Capital Employed reached 0.49% in Q3 2025 per CRVS's latest filing, up from 0.51% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.49% in Q3 2023 and bottomed at 1.64% in Q3 2024.
  • Average Return on Capital Employed over 4 years is 0.65%, with a median of 0.56% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: tumbled -115bps in 2024, then skyrocketed 115bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 0.51% in 2022, then decreased by -9bps to 0.56% in 2023, then crashed by -194bps to 1.64% in 2024, then skyrocketed by 70bps to 0.49% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.49% in Q3 2025, 0.51% in Q2 2025, and 0.53% in Q1 2025.